Angiopoietin-like 3 inhibition and the liver: less is more?

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

(2023) Robert S. Rosenson et al.   NATURE MEDICINE

GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy

(2023) Lisa N. Kasiewicz et al.   Nature Communications

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

(2023) Kausik K. Ray et al.   The Lancet Regional Health Europe

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

(2023) Gerald F. Watts et al.   NATURE MEDICINE

Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

(2022) Brian A. Bergmark et al.   CIRCULATION

The Global Burden of Cardiovascular Diseases and Risk

(2022) Muthiah Vaduganathan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Integrated Assessment of Phase 2 Data on GalNAc3-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides

(2022) Brenda F. Baker et al.   Nucleic Acid Therapeutics

New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B

(2021) Nick S. Nurmohamed et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia

(2021) Pei-Yi Chen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

(2020) Daniel Gaudet et al.   EUROPEAN HEART JOURNAL

Evinacumab for Homozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evinacumab in Patients with Refractory Hypercholesterolemia

(2020) Robert S. Rosenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

(2019) Federica Fogacci et al.   DRUGS

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

(2019) Zahid Ahmad et al.   CIRCULATION

Clinical review on triglycerides

(2019) Ulrich Laufs et al.   EUROPEAN HEART JOURNAL

Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol

(2018) Yu-Xin Xu et al.   ATHEROSCLEROSIS

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Angiopoietin-like 3 in lipoprotein metabolism

(2017) Sander Kersten   Nature Reviews Endocrinology

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

(2017) Mark J. Graham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation

(2014) Anna Tikka et al.   BIOSCIENCE REPORTS

Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis

(2013) Ilenia Minicocci et al.   JOURNAL OF LIPID RESEARCH

Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia

(2010) Kiran Musunuru et al.   NEW ENGLAND JOURNAL OF MEDICINE